{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:38:03Z","timestamp":1793723883904,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["154321"],"award-info":[{"award-number":["154321"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.xcrm.2021.100387","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T10:41:54Z","timestamp":1630665714000},"page":"100387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes"],"prefix":"10.1016","volume":"2","author":[{"given":"Rune V.","family":"Overgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin L.","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen H.","family":"Ingwersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Navarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Drucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2021.100387_bib1","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/dci19-0002","article-title":"Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground","volume":"42","author":"Home","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xcrm.2021.100387_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14737167.2020.1763796","article-title":"Cardiovascular outcome trials of glucose-lowering therapies","volume":"20","author":"Khunti","year":"2020","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.xcrm.2021.100387_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019\u00a0Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xcrm.2021.100387_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.xcrm.2021.100387_bib5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2021.100387_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The Discovery and Development of Liraglutide and Semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.xcrm.2021.100387_bib7","doi-asserted-by":"crossref","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2021.100387_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2021.100387_bib9","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xcrm.2021.100387_bib10","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xcrm.2021.100387_bib11","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2021.100387_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.xcrm.2021.100387_bib13","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xcrm.2021.100387_bib14","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cmet.2017.04.013","article-title":"A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism","volume":"25","author":"Grasset","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2021.100387_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41588-018-0332-4","article-title":"Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population","volume":"51","author":"Suzuki","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2021.100387_bib16","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s13300-018-0458-5","article-title":"Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis","volume":"9","author":"Carlsson Petri","year":"2018","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.xcrm.2021.100387_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","article-title":"Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials","volume":"55","author":"Geiser","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.xcrm.2021.100387_bib38","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1177\/0091270011430504","article-title":"Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment","volume":"52","author":"Ingwersen","year":"2012","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2021.100387_bib17","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2021.100387_bib18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2021.100387_bib19","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1172\/JCI78371","article-title":"Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight","volume":"124","author":"Baggio","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2021.100387_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/db20-0361","article-title":"Glucose Sensing Mediated by Portal Glucagon-Like Peptide 1 Receptor Is Markedly Impaired in Insulin-Resistant Obese Animals","volume":"70","author":"Malbert","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.xcrm.2021.100387_bib21","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2337\/diabetes.50.8.1720","article-title":"Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor","volume":"50","author":"Burcelin","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.xcrm.2021.100387_bib22","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/en.2006-0153","article-title":"Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats","volume":"148","author":"Vahl","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.xcrm.2021.100387_bib23","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1152\/ajpendo.00298.2019","article-title":"Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats","volume":"318","author":"Aulinger","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2021.100387_bib24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cmet.2019.08.009","article-title":"Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice","volume":"30","author":"Song","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2021.100387_bib26","article-title":"Random glucose GWAS in 493,036 individuals provides insights into diabetes pathophysiology, complications and treatment stratification","author":"Lagou","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.xcrm.2021.100387_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/pgs-2018-0159","article-title":"GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients","volume":"20","author":"Yu","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.xcrm.2021.100387_bib28","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00228-015-1868-1","article-title":"Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study","volume":"71","author":"Jensterle","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2021.100387_bib29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.xcrm.2021.100387_bib30","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2021.100387_bib31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2021.100387_bib32","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/dom.13358","article-title":"Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes","volume":"20","author":"Petri","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.xcrm.2021.100387_bib33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dom.12639","article-title":"Exposure-response analyses of liraglutide 3.0\u2009mg for weight management","volume":"18","author":"Wilding","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.xcrm.2021.100387_bib34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2021.100387_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cmet.2018.05.008","article-title":"Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist","volume":"28","author":"Iepsen","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2021.100387_bib36","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/17425255.2018.1488965","article-title":"A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide","volume":"14","author":"B\u00e6kdal","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.xcrm.2021.100387_bib37","doi-asserted-by":"crossref","first-page":"E891","DOI":"10.1152\/ajpendo.00628.2020","article-title":"Importance of the route of insulin delivery to its control of glucose metabolism","volume":"320","author":"Edgerton","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2021.100387_bib39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.xcrm.2021.100387_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2021.100387_bib41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcph.443","article-title":"Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel","volume":"55","author":"Kapitza","year":"2015","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2021.100387_bib42","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s13300-019-0581-y","article-title":"Population Pharmacokinetics of Semaglutide for Type 2 Diabetes","volume":"10","author":"Overgaard","year":"2019","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.xcrm.2021.100387_bib43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pst.403","article-title":"Confirmatory analysis for phase III population pharmacokinetics","volume":"10","author":"Hu","year":"2011","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.xcrm.2021.100387_bib44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/psp4.12015","article-title":"Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development","volume":"4","author":"Overgaard","year":"2015","journal-title":"CPT Pharmacometrics Syst. Pharmacol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379121002457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379121002457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:48:33Z","timestamp":1762987713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379121002457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2666379121002457"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2021.100387","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2021.100387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100387"}}